BIOMAT Database Logo BIOMAT Database Logo

Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. 2000

G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard

UI MeSH Term Description Entries
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
May 2000, AIDS (London, England),
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
April 2005, BMC infectious diseases,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
June 2005, AIDS (London, England),
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
February 2003, Antiviral therapy,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
February 2002, Sexually transmitted infections,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
September 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
January 2003, HIV clinical trials,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
August 2001, AIDS (London, England),
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
October 2008, BMC infectious diseases,
G J Moyle, and E Wilkins, and C Leen, and A Cheesbrough, and B Reynolds, and B G Gazzard
Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
May 2002, AIDS (London, England),
Copied contents to your clipboard!